MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory fu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Pharm Sin B
Hlavní autoři: Abdelfatah, Sara, Berg, Angela, Huang, Qi, Yang, Li Jun, Hamdoun, Sami, Klinger, Anette, Greten, Henry J., Fleischer, Edmond, Berg, Thorsten, Wong, Vincent K.W., Efferth, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2019
Témata:
Original article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804483/
https://ncbi.nlm.nih.gov/pubmed/31649851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2019.02.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky